United Kingdom

People: TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

17 Aug 2018
Change (% chg)

$0.20 (+1.76%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Hoberman, Kenneth 

Mr. Kenneth Hoberman serves as Independent Director of the Company. Mr. Hoberman is currently the Chief Operating Officer and Corporate Secretary of Stemline Therapeutics, Inc. where he was a key member of the founding team. He was instrumental in the company's financings from early private, including institutional, rounds through the IPO and subsequent follow-on offerings. He has extensive financial, accounting, investor relations, corporate governance and business development experience including M&A, strategic alliances and partnerships both domestic and international. His operational expertise includes regulatory oversight, human resources, manufacturing and clinical development. He was previously Vice President of Corporate and Business Development of Keryx Biopharmaceuticals, Inc., where he was instrumental in the success of the company. He also helped secure multiple sources of capital including over $200 million in equity investments through public and private offerings. He also initiated and executed a $100 million strategic alliance and originated, negotiated and closed dozens of licensing and operational contracts, helping to grow the company's market capitalization to over $1 billion. He also led the team that originated, in-licensed, and developed Auryxia™ which gained FDA approval in 2014. He received a B.S.B.A. in Finance from Boston University and completed post-baccalaureate studies at Columbia University.

Basic Compensation

Total Annual Compensation, USD 60,824
Restricted Stock Award, USD 166,500
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 227,324

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Michael Weiss


Sean Power


Adam Waldman


Laurence Charney


Yann Echelard


Kenneth Hoberman

As Of  31 Dec 2017